RCT: Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia.
1 Apr, 2022 | 09:47h | UTCAmisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
RCT: At 8 weeks, PANSS total score improved more with amisulpride + olanzapine (−29·6) than with olanzapine + placebo (−24·1, p=0·049, d=0·396), but not vs. amisulpride + placebo (−25·2, p=0·095, d=0·29) in acutely ill patients with schizophrenia https://t.co/Se75PJ3a0N
— PfOL (@psychopharmacol) March 18, 2022